DFFN insider filings
Diffusion Pharmaceuticals Inc. — 40 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-07-05. Screen DFFN transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for DFFN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Diffusion Pharmaceuticals Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-07-05 | 4 | LANCHONEY DIANA M — Director | Option exercise (M): 232 · Disposition to issuer (D): 85 · Option exercise (M): 232 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | Hollingsworth Jane H — Director | Option exercise (M): 183 · Disposition to issuer (D): 68 · Option exercise (M): 183 (derivative) @ $0 | EDGAR |
| 2023-04-03 | 4 | LANCHONEY DIANA M — Director | Option exercise (M): 232 · Disposition to issuer (D): 85 · Option exercise (M): 232 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Hollingsworth Jane H — Director | Option exercise (M): 183 · Disposition to issuer (D): 68 · Option exercise (M): 183 (derivative) @ $0 | EDGAR |
| 2023-02-03 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Option exercise (M): 327 · Disposition to issuer (D): 121 · Option exercise (M): 327 (derivative) @ $0 | EDGAR |
| 2022-12-02 | 4 | Hollingsworth Jane H — Director | Option exercise (M): 183 · Disposition to issuer (D): 68 · Option exercise (M): 183 (derivative) @ $0 | EDGAR |
| 2022-11-02 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Option exercise (M): 327 · Disposition to issuer (D): 121 · Option exercise (M): 327 (derivative) @ $0 | EDGAR |
| 2022-09-02 | 4 | Hollingsworth Jane H — Director | Option exercise (M): 183 · Disposition to issuer (D): 67 · Option exercise (M): 183 (derivative) @ $0 | EDGAR |
| 2022-08-26 | 4 | JAEGER RAVEN — Chief Regulatory Officer | Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2022-08-03 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Option exercise (M): 327 · Disposition to issuer (D): 121 · Option exercise (M): 327 (derivative) @ $0 | EDGAR |
| 2022-06-02 | 4 | Hollingsworth Jane H — Director | Option exercise (M): 183 · Disposition to issuer (D): 67 · Option exercise (M): 183 (derivative) @ $0 | EDGAR |
| 2022-05-03 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Option exercise (M): 327 · Disposition to issuer (D): 121 · Option exercise (M): 327 (derivative) @ $0 | EDGAR |
| 2022-04-19 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Conversion (C): 100 @ $25 · Conversion (C): 100 (derivative) @ $25 | EDGAR |
| 2022-04-19 | 4 | ELDER WILLIAM ROBERT — GC & Secretary | Conversion (C): 100 @ $25 · Conversion (C): 100 (derivative) @ $25 | EDGAR |
| 2022-03-22 | 4 | ELDER WILLIAM ROBERT — GC & Secretary | Purchase (P): 5,000 (derivative) @ $0.50 | EDGAR |
| 2022-03-22 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Purchase (P): 5,000 (derivative) @ $0.50 | EDGAR |
| 2022-02-02 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Option exercise (M): 16,350 · Disposition to issuer (D): 6,049 · Option exercise (M): 16,350 (derivative) @ $0 | EDGAR |
| 2022-02-02 | 4/A | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Option exercise (M): 16,350 · Disposition to issuer (D): 6,049 · Option exercise (M): 16,350 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Hornung William Karl — Chief Financial Officer | Grant/award (A): 305,743 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | GALLOWAY CHRISTOPHER D — Chief Medical Officer | Grant/award (A): 305,743 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | ELDER WILLIAM ROBERT — GC & Secretary | Grant/award (A): 305,743 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Grant/award (A): 764,357 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Option exercise (M): 16,350 · Option exercise (M): 16,350 (derivative) @ $0 | EDGAR |
| 2021-10-15 | 4 | LANCHONEY DIANA M — Director | Grant/award (A): 83,300 (derivative) @ $0 · Grant/award (A): 83,300 (derivative) @ $0 · Grant/award (A): 69,400 (derivative) @ $0 | EDGAR |
| 2021-07-06 | 4 | Hollingsworth Jane H — Director | Grant/award (A): 83,300 (derivative) @ $0 | EDGAR |
| 2021-07-06 | 4 | LEVIN ALAN G — Director | Grant/award (A): 83,300 (derivative) @ $0 | EDGAR |
| 2021-07-06 | 4 | Adams Robert W — Director | Grant/award (A): 83,300 (derivative) @ $0 | EDGAR |
| 2021-07-06 | 4 | Francois Eric — Director | Grant/award (A): 83,300 (derivative) @ $0 · Grant/award (A): 83,300 (derivative) @ $0 · Grant/award (A): 69,400 (derivative) @ $0 | EDGAR |
| 2021-07-06 | 4 | Giles Mark T — Director | Grant/award (A): 83,300 (derivative) @ $0 | EDGAR |
| 2021-05-17 | 4 | Hollingsworth Jane H — Director | Purchase (P): 32,786 @ $0.61 | EDGAR |
| 2021-03-04 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Grant/award (A): 53,713 (derivative) @ $0 · Grant/award (A): 161,139 (derivative) @ $0 | EDGAR |
| 2021-03-04 | 4 | ELDER WILLIAM ROBERT — GC & Secretary | Grant/award (A): 87,684 (derivative) @ $0 · Grant/award (A): 62,522 (derivative) @ $0 | EDGAR |
| 2021-03-04 | 4 | GALLOWAY CHRISTOPHER D — Chief Medical Officer | Grant/award (A): 27,180 (derivative) @ $0 · Grant/award (A): 81,537 (derivative) @ $0 | EDGAR |
| 2021-03-04 | 4 | Hornung William Karl — Chief Financial Officer | Grant/award (A): 122,771 (derivative) @ $0 · Grant/award (A): 80,069 (derivative) @ $0 | EDGAR |
| 2020-11-18 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Purchase (P): 14,000 @ $0.66 | EDGAR |
| 2020-11-18 | 4 | ELDER WILLIAM ROBERT — GC & Secretary | Purchase (P): 10,000 @ $0.67 · Purchase (P): 5,000 @ $0.63 | EDGAR |
| 2020-10-21 | 4 | GALLOWAY CHRISTOPHER D — Chief Medical Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2020-10-14 | 4 | ELDER WILLIAM ROBERT — GC & Secretary | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2020-10-01 | 4 | Hollingsworth Jane H — Director | Grant/award (A): 67,400 (derivative) @ $0 · Grant/award (A): 54,900 (derivative) @ $0 | EDGAR |
| 2020-09-11 | 4 | Cobuzzi Robert Joseph Jr. — President & CEO, Director | Grant/award (A): 475,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Diffusion Pharmaceuticals Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-16 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-29 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-13 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-28 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DFFN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs